CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
perifosinedrug
Likely dose
perifosine 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00873457
NCT00873457Phase 2Completed
CompareCT.gov

Phase II Trial of Perifosine in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Daphne Friedman·interventional·Posted Apr 1, 2009·Updated May 27, 2013

In Brief

A Phase 2 clinical trial evaluating perifosine for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. Completed, enrolled 16 participants across 1 site.

Detailed Summary

Perifosine inhibits the AKT pathway (a way cells communicate with each other). This pathway is felt to be important in the development of several types of cancers including chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is thought perifosine may be able to block this pathway and lead to an improvement in the CLL or SLL. The purpose of this trial is to see if perifosine is an effective treatment for relapsed or refractory CLL or SLL. Another purpose of this study is to look at the effect perifosine has on cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
CountriesUnited States
CollaboratorsKeryx Biopharmaceuticals, Keryx / AOI Pharmaceuticals, Inc.

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 1, 2009
Enrollment StartAug 1, 2009
Primary CompletionOct 1, 2011
Study CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 17.3 years ago

Interventions

perifosinedrug

Perifosine 50 mg will be taken orally twice a day for a maximum of six 28-day cycles